Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effects of Blueberry Juice Consumption on Cognitive Function in Healthy Older People

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02985580
Recruitment Status : Completed
First Posted : December 7, 2016
Last Update Posted : December 7, 2016
Sponsor:
Information provided by (Responsible Party):
University of Exeter

Brief Summary:
Blueberries are rich in flavonoids that possess antioxidant and anti-inflammatory properties, which in rodent models are neuro-protective. The risk of developing dementia is reduced in people habitually consuming high flavonoid intakes, but data from human intervention studies is sparse. We therefore investigated whether 12 weeks of blueberry concentrate supplementation improved cognitive function in healthy elderly via increased brain activation and perfusion.

Condition or disease Intervention/treatment Phase
Cognitive Aging Dietary Supplement: Blueberry Dietary Supplement: Placebo Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 26 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: Effects of Blueberry Juice Consumption on Brain Activation and Perfusion in Healthy Older People
Study Start Date : October 2013
Actual Primary Completion Date : September 2014
Actual Study Completion Date : September 2014

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Blueberry
Blueberry concentrate consumed daily for 12 weeks.
Dietary Supplement: Blueberry
Placebo Comparator: Placebo
Placebo concentrate consumed daily for 12 weeks.
Dietary Supplement: Placebo



Primary Outcome Measures :
  1. Brain perfusion [ Time Frame: Change from baseline to 12 weeks dietary supplementation ]
    MRI - arterial spin labelling


Secondary Outcome Measures :
  1. Brain activation [ Time Frame: Change from baseline to 12 weeks dietary supplementation ]
    fMRI whilst performing modified Stroop task

  2. Cognitive function tests [ Time Frame: Change from baseline to 12 weeks dietary supplementation ]
    Cogstate battery of tests

  3. Blood biomarkers of inflammation [ Time Frame: Change from baseline to 12 weeks dietary supplementation ]
    CRP, IL6,

  4. Blood biomarkers of oxidative stress [ Time Frame: Change from baseline to 12 weeks dietary supplementation ]
    protein carbonyls, glutathione

  5. Blood biomarkers of neurogenesis [ Time Frame: Change from baseline to 12 weeks dietary supplementation ]
    BDNF



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   60 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • aged 60-80y
  • Addenbrooke's Cognitive Examination III questionnaire > 88
  • Consuming 5 or less portions of fruit per day

Exclusion Criteria:

Addenbrooke's Cognitive Examination III questionnaire < 88 Contraindications for MRI Consuming more than 5 portions of fruit per day


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02985580


Sponsors and Collaborators
University of Exeter
Investigators
Layout table for investigator information
Principal Investigator: Joanna Bowtell, PhD University of Exeter
Layout table for additonal information
Responsible Party: University of Exeter
ClinicalTrials.gov Identifier: NCT02985580    
Other Study ID Numbers: 1314/134617
First Posted: December 7, 2016    Key Record Dates
Last Update Posted: December 7, 2016
Last Verified: September 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No